Orthofix(OFIX) Prnewswire·2024-08-22 23:00Class Action Lawsuit - A class action lawsuit has been filed against Orthofix Medical Inc (NASDAQ: OFIX) alleging securities fraud or other unlawful business practices by the company and certain officers/directors [1][2] - Shareholders who purchased Orthofix securities during the Class Period have until October 21, 2024 to request appointment as Lead Plaintiff [2] Executive Changes - On September 12, 2023, Orthofix announced the immediate appointment of interim CEO, CFO, and Chief Legal Officer following the termination of Keith Valentine, John Bostjancic and Patrick Keran from those roles [2] - The terminations resulted from an investigation that found the executives engaged in repeated inappropriate and offensive conduct violating the company's code of conduct and values [2] Stock Price Impact - Orthofix's stock price fell $5 62 per share or 30 17% to close at $13 01 per share on September 12, 2023 following the executive changes announcement [2] Law Firm Background - Pomerantz LLP, the law firm handling the class action, is a premier firm in corporate, securities and antitrust class litigation with offices in New York, Chicago, Los Angeles, London, Paris and Tel Aviv [3] - Founded over 85 years ago, Pomerantz has recovered billions of dollars in damages for class members in securities fraud and corporate misconduct cases [3]